Piasky is a medicine to treat adults and children over 12 years of age weighing 40 kg or more who have paroxysmal nocturnal haemoglobinuria (PNH). PNH is a disease in which excessive haemolysis (the breakdown of red blood cells) results in anaemia (low levels of haemoglobin, the protein in red blood cells that carries oxygen around the body), thrombosis (blood clots in blood vessels), pancytopenia (low levels of blood cells) and dark urine (due to large amounts of haemoglobin being released into the urine). Piasky is used in patients with haemolysis and symptoms of high disease activity, and in patients who have been stable on treatment with a C5 inhibitor (another medicine used to treat PNH) for at least 6 months. Piasky contains the active substance crovalimab.
Therapeutic Indication
### Therapeutic indication Piasky as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): - In patients with haemolysis with clinical symptom(s) indicative of high disease activity. - In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
Therapeutic Area (MeSH)
ATC Code
L04AJ07
ATC Item
crovalimab
Pharmacotherapeutic Group
Immunosuppressants, Complement inhibitors
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Crovalimab | N/A | 可伐利单抗 |
EMA Name
Piasky
Medicine Name
Piasky
Aliases
N/ANo risk management plan link.
